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We have read the article ‘Preventive effect
of dapsone on renal scarring following man-
nose-sensitive piliated bacterial infection’ by
Mochida and co-workers [6] with interest.
Since a few years we are dealing with the
modes of action of dapsone, with aspects of
clinical use and side effects [9,11, 12], we are
aware of a possibly potential new indication
for the sulfone. Indeed we agree with the
author’s statement that the anti-inflammatory
effects of dapsone are exerted, at least partial-
ly, by the inhibition of reactive oxygen species
(ROS). However, in recent years there are sev-
eral lines of evidence of additional mecha-
nisms of actions of the sulfone which have
been demonstrated using in vitro methods:
(I) Suppression of the integrin-mediated neu-
trophilic adherence [2].
(II) Inhibition of generation of 5-lipoxygenase
products (e.g. LTB4, 12-HETE) [13].
(III) Inhibition of spontaneous or induced
synthesis of prostaglandin E2 [7].
(IV) Inhibition of cyclooxygenase I- and II-me-
diated generation of thromboxane B2 [5].
(V) Interference with activation or function of
the G-protein (Gi-type) resulting in an in-
hibition of signal transduction [3].
Moreover, it has been shown that dapsone
has neuroprotective effects against quinolate-
and kainate-induced striatal neurotoxicities
in rats [8] and attenuates kainic-induced sei-
zures in rats [4]. Summarizing these different
mechanisms, there is growing evidence that
dapsone is pharmacodynamically a very ac-
tive compound.
From the clinical point of view dapsone is
especially effective in those disorders in
which the polymorphonuclear neutrophil leu-
kocyte (PMN) morphologically and/or func-
tionally seems to play a central role. On the
other hand, dapsone is acetylated in the liver
to monoacetyldapsone (MADDS), which is
genetically determined [15]. The drug is al-
so hydroxylated to hydroxylamine dapsone
(DDS-NOH). The latter metabolite has to be
seen as being responsible for adverse hemato-
logic effects induced by the drug (e.g. methe-
moglobinemia, hemolysis) [15].
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To date, however, the anti-inflammatory
capacity of dapsone was generally attributed
to the parent compound itself. We have there-
fore addressed the question as to whether
these two major metabolites of dapsone DDS-
NOH and MADDS have anti-inflammatory
properties of their own in vivo. After mea-
surement of the leukotriene B4-induced accu-
mulation of PMN in healthy skin, we could
demonstrate that DDS-NOH has a strong
anti-inflammatory effect whereas dapsone
and MADDS did not reveal any activity [14].
An additional in vivo study using healthy vol-
unteers revealed an intenser erythema-sup-
pressing effect of DDS-NOH compared to
dapsone (unpublished observations). In an
other investigation, we were again able to
show that DDS-NOH is more active in inhib-
iting the generation of 5-lipoxygenase prod-
ucts in comparison to dapsone confirming the
anti-inflammatory properties of DDS-NOH
[10].
Thus, it is very attractive to speculate that
DDS-NOH in vivo has anti-inflammatory po-
tential. As in the investigation of Mochida
and co-workers, dapsone systemically was
used in rats and it cannot be excluded that in
this experiment DDS-NOH might contribute
to the effectiveness of dapsone therapy.
It is becoming increasingly clear that dap-
sone metabolites should be given more notice
than they have till now. To obtain a more pre-
cise understanding of the mechanisms of ac-
tion of dapsone therapy, further investiga-
tions should confirm our hypothesis.
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